News Medical on MSN3 天
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer
One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
Novel CAR T-cell therapy demonstrates efficacy and safety in preclinical models of HER2 ...
One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer
Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...
technologynetworks3 天
CAR T-Cell Therapy Shows Promise in Preclinical Models of HER2-Positive Solid Tumors
T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...
FiercePharma1 天
Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu
The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...
Medscape1 天
FDA Approves Bispecific HER2 Antibody for Biliary Tract Cancer
Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.
WebMD10 小时
FDA Approves New Targeted Treatment for Biliary Tract Cancer
The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand name Ziihera, it is a first-of-a-kind treatment for patients with ...